x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Through pathological research, we can better understand the mechanisms, development rules of T1DM, and metabolism in the process of diseases, which is helpful for the development of therapies. Ace Therapeutics provides pathological research programs and materials for research T1DM, mainly including animal models and other experimental materials.
The studies have demonstrated that the disease occurs as a consequence of a breakdown in immune regulation, resulting in the expansion of autoreactive CD4+ and CD8+ T cells, autoantibody-producing B lymphocytes, and activation of the innate immune system that collaborate to destroy the insulin-producing β-cells. It is estimated that about 40-50% of the risk of T1DM is related to major histocompatibility complex (MHC) complex or IDDM1 locus.
Non-obese diabetes (NOD) mouse, as the main animal model of T1DM, have many aspects in common with the human disease, including a number of similarities in genetic loci of susceptibility, influence of the environment and pathogenesis of disease. There are now at least 26 known genetic susceptibility loci for T1DM. The most important are IDDM1, IDDM2, PTPN22, et al.
| IDDM1 | IDDM1 is located at 6p21 of human chromosome, which contains HLA genes. |
| IDDM2 | This gene is located on human chromosome 11p15 and contains the insulin gene. |
| PTPN22 | PTPN22 is protein tyrosine phosphatase gene, which has mutations on LYP (lymphocyte specific phosphatase gene) on chromosome 1. |
| IDDM12 | the IDDM12 locus contains some genes that may cause diabetes. The CTLA4, CD28 and ICOS can inhibit some functions of T cells. |
With years of experience in translational medicine research and drug development, Ace Therapeutics is able to provide research services to study the genes, biochemical pathways, modules and their action networks related to diabetes at the molecular and cellular levels, and carry out integration and systematic analysis. Our services include but not limited to the followings.
Highly Customizable
One-stop Services
High Quality
Professional Team
Ace Therapeutics offers cost-effect and high-quality research services related to T1DM for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
